Biotech / Finance

Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study

From RTT - Biotech
March 18, 2017 - 9:44pm
Amgen Inc. (AMGN) announced results from the Repatha or evolocumab cognitive function trial (EBBINGHAUS) evaluating the impact on cognitive function in 1,974 patients enrolled in the Repatha cardiovascular outcomes study, FOURIER.

Continue reading this article »